ASCO 2017 | Understanding the RPL10 R98S mutation in T-ALL

Name: Understanding the RPL10 R98S mutation in T-ALL
Uploaded: 2017-06-22T00:00:00.000Z
Duration: 1 min 22 s

Kim Kampen • 22 Jun 2017

ASCO 2017 EHA 2017

T-Cell Lymphoma

Kim Kampen, PhD, University of Leuven, Leuven, Belgium, talks to us about the recent discovery of the ribosomal protein L10 (RPL10) R98S mutation, which occurs in 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases. Currently, researchers are working to understand the mechanism, drive and cause of the mutation with the aim of using this information to determine potential therapeutic targets for treatment of T-ALL. She mentions that T-ALL patients carrying the mutation have been shown to express higher levels of Bcl2, a pro-survival protein, which raises the possibility of targeting Bcl2 to treat the disease. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.